BICYCLIC NITROGENATED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
申请人:Shionogi & Co., Ltd
公开号:EP3527568A1
公开(公告)日:2019-08-21
Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. A compound represented by Formula (I):
wherein Z1 is C(R4) or the like; R4 is a hydrogen atom or the like; Z2 is C(R5a)(R5a') or the like; the dashed line represents the presence or absence of a bond; when the dashed line represents the presence of a bond, then R5a' is absent; R5a and R5a' are each independently a hydrogen atom or the like; Ring Q is a substituted or unsubstituted 5-membered non-aromatic heterocycle or the like; Y1 is O or the like; R2a is a group represented by the formula: -(C(R2a')(R2b'))n-R1; R2b is a hydrogen atom or the like; R2a' and R2b' is each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; n is an integer from 0 to 4; and m is an integer from 0 to 4, or a pharmaceutically acceptable salt thereof.
Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same
申请人:Shionogi & Co., Ltd.
公开号:US11066409B2
公开(公告)日:2021-07-20
Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I):
wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.
BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
申请人:Shionogi & Co., Ltd.
公开号:US20200048257A1
公开(公告)日:2020-02-13
Provided are a novel compound having an antagonistic activity for the P2X
7
receptor, and a pharmaceutical composition having an antagonistic activity for the P2X
7
receptor. The compound represented by Formula (I):
wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.